CTMX Valuation

CytomX Therapeutics Inc

Add to Watchlist

Advanced Chart

0.532

+0.038(+7.680%)

Overview
Forecast
Valuation

CTMX Relative Valuation

CTMX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTMX is overvalued; if below, it's undervalued.

Historical Valuation

CytomX Therapeutics Inc (CTMX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.39 is considered Undervalued compared with the five-year average of 2.86. The fair price of CytomX Therapeutics Inc (CTMX) is between 1.23 to 5.34 according to relative valuation methord. Compared to the current price of 0.53 USD , CytomX Therapeutics Inc is Undervalued By 56.71%.

Relative Value

Fair Zone

1.23-5.34

Current Price：0.53

56.71%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-93.55

P/B

Median3y

-5.59

Median5y

-31.46

-218.44

FCF Yield

Median3y

-91.45

Median5y

-62.18

Competitors Valuation Multiple

The average P/S ratio for CTMX's competitors is 0.56, providing a benchmark for relative valuation. CytomX Therapeutics Inc Corp (CTMX) exhibits a P/S ratio of 0.39, which is -29.70% above the industry average. Given its robust revenue growth of 43.17%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

CTMX.O

CytomX Therapeutics Inc